Research Analysts’ Recent Ratings Changes for Axsome Therapeutics (AXSM)

A number of firms have modified their ratings and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) recently:

• 2/12/2025 – Axsome Therapeutics had its price target raised by analysts at Wells Fargo & Company from $140.00 to $160.00. They now have an “overweight” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its price target raised by analysts at Mizuho from $137.00 to $195.00. They now have an “outperform” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its price target raised by analysts at Bank of America Co. from $143.00 to $167.00. They now have a “buy” rating on the stock.
• 2/11/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
• 2/11/2025 – Axsome Therapeutics is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $176.00 price target on the stock.
• 2/10/2025 – Axsome Therapeutics had its price target raised by analysts at Leerink Partners from $110.00 to $150.00. They now have an “outperform” rating on the stock.
• 2/10/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 2/3/2025 – Axsome Therapeutics had its price target raised by analysts at Mizuho from $122.00 to $137.00. They now have an “outperform” rating on the stock.
• 2/3/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $180.00 to $190.00. They now have a “buy” rating on the stock.
• 1/31/2025 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $180.00 to $190.00. They now have a “buy” rating on the stock.
• 1/29/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $139.00 price target on the stock.
• 1/24/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/21/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $150.00 to $180.00. They now have a “buy” rating on the stock.
• 1/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 12/31/2024 – Axsome Therapeutics had its price target lowered by analysts at Mizuho from $124.00 to $122.00. They now have an “outperform” rating on the stock.
• 12/31/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/30/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $131.15 on Tuesday. The stock has a 50 day moving average price of $98.47 and a 200 day moving average price of $93.68. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $134.18.

Insider Activity at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently modified their holdings of the company. BVF Inc. IL boosted its holdings in shares of Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock valued at $117,444,000 after acquiring an additional 342,064 shares during the period. FMR LLC boosted its holdings in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock valued at $77,228,000 after acquiring an additional 4,079 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Axsome Therapeutics by 10.8% in the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock valued at $58,589,000 after acquiring an additional 67,285 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.